{"slideshow_credits": null, "snippet": "Novartis and a patent lawyer discuss its patent request for the leukemia drug Gleevec.", "abstract": null, "section_name": "Opinion", "print_page": "20", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2013/04/13/opinion/indias-ruling-on-a-novartis-drug-2-perspectives.html", "lead_paragraph": "Novartis and a patent lawyer discuss its patent request for the leukemia drug Gleevec.", "headline": {"main": "India\u2019s Ruling on a Novartis Drug: 2 Perspectives", "print_headline": "India\u2019s Ruling on a Novartis Drug: 2 Perspectives", "content_kicker": "Letters", "kicker": "Letters"}, "_id": "5168955dcf28d02a61000060", "word_count": "435", "multimedia": [], "pub_date": "2013-04-13T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"value": "Novartis AG", "name": "organizations", "is_major": "N", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Inventions and Patents", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Decisions and Verdicts", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Intellectual Property", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "India", "name": "glocations", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}